Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 0.00.
Sobreavaliada
O PE mais recente da empresa é -1.52, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 82.28M ações, uma redução de 14.66% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 92.59K ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.71.